Gilead Sciences, Inc.

GILDNASDAQHealthcare● Active

$129.16

$-0.02(-0.02%)

Market Cap$160.4B

P/E Ratio—

52W High$157.29

52W Low$104.46

Avg Volume6.1M

Open$130.37

Beta0.33

Overview

Gilead Sciences, Inc. (GILD) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

GILD · free cash flow · updated Jun 8, 2026

Core FCF metrics

GILD · FCF · TTM · margin & CAGR

Free cash flow was $9.46B for FY2025 (fiscal year ending 2025-12-31), down 8.2% year-over-year The FCF margin was 32.1%. Five-year CAGR stands at +4.7%.

FY2025 Free Cash Flow$9.46B▼ -8.2% YoY

Trailing 12M (TTM)$10.23Btrailing 4 quarters sum

FCF Margin32.1%$9.46B ÷ revenue

3-Year CAGR+4.3%FY2022 → FY2025

5-Year CAGR+4.7%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

GILD · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$10.02B(563M)$9.46B▼ 8.2%32.1%

FY2024$10.83B(523M)$10.30B▲ +38.9%35.8%

FY2023$8.01B(585M)$7.42B▼ 11.1%27.4%

FY2022$9.07B(728M)$8.34B▼ 22.8%30.6%

FY2021$11.38B(579M)$10.80B▲ +43.7%39.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

GILD · P/FCF · FCF yield · FCF per share

Gilead Sciences, Inc. (GILD) trades at a FCF yield of 6.38% and a price-to-free-cash-flow ratio of 15.7x. FCF per share stands at $8.22, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

6.38%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$8.22

TTM FCF ÷ Shares Outstanding

Price / FCF

x15.7

Share Price ÷ FCF per Share

EV / FCF (TTM)

x17.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

GILD · cash flow statement · operating / investing / financing

For FY2025, Gilead Sciences, Inc. generated $10.02B in operating cash flow and spent 563M in capital expenditures, yielding $9.46B in free cash flow.

Operating Activities

+$10.02B

Cash from core business operations

2025-12-31

Investing Activities

−$4.79B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$7.75B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($10.02B) − |CapEx| (563M) = FCF ($9.46B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

GILD vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Gilead Sciences, Inc.YOU

GILD

$9.46B-8.2%32.1%

48%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Gilead Sciences, Inc. (GILD) reported free cash flow of $9.46B for FY2025 (fiscal year ending 2025-12-31), down 8.2% year-over-year. The FCF margin was 32.1%.

Based on available data, Gilead Sciences, Inc. has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $20.50B in FY2015. The 5-year CAGR stands at +4.7%.

Gilead Sciences, Inc.'s FCF yield is 6.38% and price-to-FCF ratio is 15.7x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

GILD free cash flow · 8 questions

Gilead Sciences, Inc. free cash flow was $9.46B for FY2025, down 8.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $10.23B.

GILD free cash flowGILD FCFGILD FCF 2025GILD free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Gilead Sciences, Inc. · Gilead Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026